Mirikizumab clinical trials
Also written LY3074828 and Omvoh.
How each study uses mirikizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mirikizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Oct 2023 · OMVOH · BLA 761279 (FDA, Drugs@FDA)
- European Union
- 26 May 2023 · Omvoh · EMEA/H/C/005122 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
44 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 36 · Other 8
Eli Lilly and Company (35) · University Hospital Schleswig-Holstein (2) · University of North Carolina, Chapel Hill (1) · Showa Inan General Hospital (1) · Specialty Networks Research. (1) · Icahn School of Medicine at Mount Sinai (1) · Rubix LS (1) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (1)
Often tested with
Tested in the same studies.
LY900021 (2) · Vedolizumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test mirikizumab.
- Feb 2027A Study of Mirikizumab Solution (LY3074828) in Healthy ParticipantsPhase 1 · Eli Lilly and Company
- Sep 2027Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CDPhase 4 · Alimentiv Inc.
- Oct 2027Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the PouchPhase 4 · University of North Carolina, Chapel Hill
- Nov 2027Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's DiseasePhase 4 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Studies
Open first, then newest update. How each study uses mirikizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 44
- Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's DiseaseRecruitingPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT07292012Written as Mirikizumab - IV
- A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved IndicationRecruitingPhase 4Eli Lilly and CompanyNCT07612267Written as Mirikizumab
- INSIGHT-IBD Pragmatic StudyEnrolling by invitationPhase 4Specialty Networks Research.NCT07686757Written as Mirikizumab
- Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CDRecruitingPhase 4Alimentiv Inc.NCT06997965Written as Mirikizumab
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)RecruitingPhase 3Eli Lilly and CompanyNCT04844606Written as Mirikizumab
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's DiseaseRecruitingPhase 3Eli Lilly and CompanyNCT05509777Written as Mirikizumab
- MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's DiseaseNot yet recruitingPhase 4Icahn School of Medicine at Mount SinaiNCT07782021Written as Mirikizumab
- Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's DiseaseNot yet recruitingPhase 4University Hospital Schleswig-HolsteinNCT07659353Written as Mirikizumab
- A Study of Mirikizumab Solution (LY3074828) in Healthy ParticipantsRecruitingPhase 1Eli Lilly and CompanyNCT07446101Written as Mirikizumab
- Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative ColitisRecruitingPhase 4University Hospital Schleswig-HolsteinNCT07235904Written as Mirikizumab
- Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative ColitisNot yet recruitingPhase 4Rubix LSNCT07059130Written as Mirikizumab
- Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the PouchActive, not recruitingPhase 4University of North Carolina, Chapel HillNCT06864403Written as Mirikizumab - Intravenous (IV)
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseActive, not recruitingPhase 3Eli Lilly and CompanyNCT04232553Written as Mirikizumab
- A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Eli Lilly and CompanyNCT05767021Written as Mirikizumab
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisCompletedPhase 3Eli Lilly and CompanyNCT05784246Written as Mirikizumab IV
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Eli Lilly and CompanyNCT03524092Written as Mirikizumab SC
- A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Active, not recruitingPhase 3Eli Lilly and CompanyNCT03519945Written as Mirikizumab
- A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06475729Written as Citrate-Free Mirikizumab
- Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic MucosaCompletedPhase 4Showa Inan General HospitalNCT06626165Written as Mirikizumab
- An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)CompletedPhase 3Eli Lilly and CompanyNCT03518086Written as Mirikizumab
See all 44 studies that test mirikizumab →
Given beside what is tested · 7 — mirikizumab is usual care or a partner of the new treatment
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingPhase 3Eli Lilly and CompanyNCT06937086Written as Mirikizumab
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT06937099Written as Mirikizumab
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:RecruitingPhase 2Eli Lilly and CompanyNCT07186101Written as Mirikizumab
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseRecruitingPhase 2Eli Lilly and CompanyNCT07483099Written as Mirikizumab - Intravenous (IV)
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseRecruitingPhase 2Eli Lilly and CompanyNCT07483073Written as Mirikizumab - Intravenous (IV)
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 2Eli Lilly and CompanyNCT06598943Written as Mirikizumab
- A Study of Injections of LY3074828 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03886948Written as LY3074828
Codes
What other systems call mirikizumab · ClinicalTrials.gg INT001359
- MeSH (NLM) C000708407mirikizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Z7HVY03PHPMIRIKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q55641096mirikizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170182MirikizumabOne source FDA
- DrugBank DB14910One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708407 | mirikizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Z7HVY03PHP | MIRIKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q55641096 | mirikizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170182 | Mirikizumab | One source FDA |
| DrugBank | DB14910 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.